Asthma and COPD

Our monotherapies, bi-therapies and tri-therapies

InhaTarget Therapeutics has developed dry powders for inhalation (DPI) specifically tailored to treat asthma and chronic obstructive pulmonary disease (COPD). These include advantageous and targeted monotherapies, bi-therapies and tri-therapies to treat said diseases with an optimized benefit/risk ratio.

The developed dry powders allow to reach very high drug(s) deposition in the lungs. Different APIs are combined in these original formulations to obtain an optimal therapeutic effect. The originality of these formulations are related to the modification of the API physical properties (e.g. size, shape, dissolution profile) to optimize their deposition in the respiratory tract and increase their therapeutic activity.

Relevant publications

Impact of different capsules for dry powder inhalers on the aerodynamic performances of formoterol-based binary and ternary blends
N. Wauthoz, I. Hennia, S. Ecenarro, K. Amighi. Drug Delivery to the Lung 2016, Edinburg (UK), 7-9 December 2016

Evaluation of the content homogeneity and dispersion properties of fluticasone DPI compositions
T. Sebti, F. Vanderbist and K. Amighi. J. Drug Del. Sc. Technol., 17(3) 223-229 (2007)

Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation
T. Sebti, G. Pilcer, B. Van Gansbeke, S. Goldman, A. Michils, F. Vanderbist and K. Amighi. Eur. J. Pharm. Biopharm., 64, 26-32 (2006)

Sed dictum ipsum risus. libero Donec nec